(Reuters) – Britain’s GSK said on Tuesday it will develop and test a potential COVID-19 vaccine using its booster technology and Canadian biopharmaceutical firm Medicago’s coronavirus-like particles.
GSK, the world’s largest vaccine maker, said the companies aim to make their vaccine available in the first half of next year and produce about 100 million doses by the end of 2021. Early stage testing in humans is expected to begin in mid-July.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shinjini Ganguli)
